DDInter603 DDInter927
A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Droperidol {u} (Compound) resembles {v} (Compound) Haloperidol
Droperidol {u} (Compound) resembles {v} (Compound) Fluspirilene
Droperidol {u} (Compound) binds {v} (Gene) ADRA1A
Droperidol {u} (Compound) is included by {v} (Pharmacologic Class) Dopamine D2 Antagonists
Droperidol {u} (Compound) downregulates {v} (Gene) CHIC2
Droperidol {u} (Compound) causes {v} (Side Effect) Altered state of consciousness
Droperidol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Droperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextromethorphan
Droperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Droperidol {u} may lead to a major life threatening interaction when taken with {v} Naloxone
Droperidol (Compound) resembles Haloperidol (Compound)
Droperidol (Compound) resembles Fluspirilene (Compound)
Droperidol (Compound) binds ADRA1A (Gene)
Droperidol (Compound) is included by Dopamine D2 Antagonists (Pharmacologic Class)
Droperidol (Compound) downregulates CHIC2 (Gene)
Droperidol (Compound) causes Altered state of consciousness (Side Effect)
Droperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Droperidol may lead to a major life threatening interaction when taken with Naloxone